ATE400653T1 - Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen - Google Patents

Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen

Info

Publication number
ATE400653T1
ATE400653T1 AT96925537T AT96925537T ATE400653T1 AT E400653 T1 ATE400653 T1 AT E400653T1 AT 96925537 T AT96925537 T AT 96925537T AT 96925537 T AT96925537 T AT 96925537T AT E400653 T1 ATE400653 T1 AT E400653T1
Authority
AT
Austria
Prior art keywords
receptors
compounds
activity
metabotropic glutamate
metabotropic
Prior art date
Application number
AT96925537T
Other languages
English (en)
Inventor
Forrest H Fuller
Karen J Krapcho
Lance G Hammerland
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE400653T1 publication Critical patent/ATE400653T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96925537T 1995-07-26 1996-07-25 Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen ATE400653T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US152695P 1995-07-26 1995-07-26

Publications (1)

Publication Number Publication Date
ATE400653T1 true ATE400653T1 (de) 2008-07-15

Family

ID=21696494

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96925537T ATE400653T1 (de) 1995-07-26 1996-07-25 Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen

Country Status (10)

Country Link
US (3) US5981195A (de)
EP (1) EP0783577B1 (de)
JP (2) JPH10507934A (de)
AT (1) ATE400653T1 (de)
AU (1) AU710128B2 (de)
CA (1) CA2200606A1 (de)
DE (1) DE69637587D1 (de)
ES (1) ES2308779T3 (de)
IL (2) IL120424A0 (de)
WO (1) WO1997005252A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU750179B2 (en) * 1995-07-26 2002-07-11 Astrazeneca Ab Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
WO1997005252A2 (en) * 1995-07-26 1997-02-13 Nps Pharmaceuticals, Inc. Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
US6084084A (en) * 1996-02-21 2000-07-04 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
WO1999021992A2 (en) * 1997-10-23 1999-05-06 Ganimed Pharmaceuticals Gmbh Nucleic acid molecules encoding a glutamate receptor
AU768422B2 (en) * 1998-04-03 2003-12-11 Astrazeneca Ab G-protein fusion receptors and chimeric GABAb receptors
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
US6500431B1 (en) * 1998-07-13 2002-12-31 University Of Southern California Inhibitors of angiogenesis and tumor growth
CH1196397H1 (de) 1999-06-02 2007-05-31 Nps Pharma Inc Metabotrope Glutamatrezeptorantagonisten zur Behandlung von Krankheiten des zentralen Nervensystems.
US6534287B1 (en) 1999-10-25 2003-03-18 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
EP1257579B1 (de) * 2000-02-04 2009-08-05 Lexicon Pharmaceuticals, Inc. Neue menschliche g-protein gekoppelten rezeptoren und dafür kodierende polynucleotide
CA2403633A1 (en) * 2000-03-28 2001-10-04 Lexicon Genetics Incorporated Human 7-transmembrane proteins and polynucleotides encoding the same
WO2002008290A1 (en) 2000-07-21 2002-01-31 Merck & Co., Inc. Dog melanin-concentrating hormone receptor
DE60134497D1 (de) * 2000-10-03 2008-07-31 Astrazeneca Ab G-protein fusionsrezeptoren
CN1714151A (zh) * 2000-12-22 2005-12-28 惠氏公司 新的谷氨酸受体调节蛋白和核酸分子及其用途
US20100248268A1 (en) * 2001-03-27 2010-09-30 Woods Daniel F Methods to utilize invertebrate chemosensory proteins for industrial and commercial uses
US20070003980A1 (en) * 2001-03-27 2007-01-04 Woods Daniel F Efficient methods to isolate effectors of proteins involved in olfactory or chemosensory pathways and efficient methods to use these effectors to alter organism olfaction, chemosensation, or behavior
EP1588139A4 (de) 2001-05-31 2006-10-04 Merck & Co Inc Melaninanreicherungshormon-rezeptor typ 2 aus rhesusaffe, hund und frettchen
EP1445314B1 (de) * 2001-10-23 2011-09-14 Ajinomoto Co., Inc. Neuer glutaminsäurerezeptor und dessen verwendung
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
JP2006515271A (ja) 2002-07-23 2006-05-25 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス グレリン類似体
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
US20050186658A1 (en) * 2003-10-17 2005-08-25 Nps Pharmaceuticals, Inc. Chimeric metabotropic glutamate receptors and uses thereof
DK1937262T3 (da) 2005-09-29 2019-07-15 Ipsen Pharma Sammensætning til anvendelse i behandling af gastrointestinal dysmotilitet
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
CA2840458C (en) * 2011-06-24 2020-09-22 Haag-Streit Medtech Ag Light-sensitive chimeric gpcr protein
EP3281608B1 (de) 2012-02-10 2020-09-16 CVDevices, LLC Produit medical contenant une armature et plèvre viscérale
AU2014214700B2 (en) 2013-02-11 2018-01-18 Cook Medical Technologies Llc Expandable support frame and medical device
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
CN114729009A (zh) 2019-10-31 2022-07-08 伯尔尼大学 用于眼部基因递送的aav载体变体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5030576A (en) * 1986-04-30 1991-07-09 Genentech, Inc. Receptors for efficient determination of ligands and their antagonists or agonists
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
NZ240921A (en) * 1990-12-12 1994-06-27 Zymogenetics Inc G protein coupled glutamate receptor (neurotransmitters), recombinant production
DE69222637T2 (de) * 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
CA2094987A1 (en) * 1992-05-01 1993-11-02 James P. Burnett, Jr. Human glutamate receptor proteins and associated dna compounds
IL105587A0 (en) * 1992-05-08 1993-09-22 Lilly Co Eli Human metabotropic glutamate receptor and related dna compounds
AU3777093A (en) * 1993-02-23 1994-09-14 Brigham And Women's Hospital Calcium receptor-active molecules
US5521297A (en) * 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
FI961251L (fi) * 1993-09-20 1996-03-18 Ciba Geigy Ihmisten metabotrooppiset glutamaattireseptorialatyypit(HMR4, HMR6, HMR7)ja niihin liittyvät DNA-yhdisteet
EP1275635A1 (de) * 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Kalzium-Rezeptor aktive Verbindungen
TW502026B (en) * 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
WO1997005252A2 (en) * 1995-07-26 1997-02-13 Nps Pharmaceuticals, Inc. Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
US6084084A (en) * 1996-02-21 2000-07-04 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
US6288610B1 (en) * 1998-03-19 2001-09-11 Fujitsu Limited Method and apparatus for correcting signals, apparatus for compensating for distortion, apparatus for preparing distortion compensating data, and transmitter
CN1714151A (zh) * 2000-12-22 2005-12-28 惠氏公司 新的谷氨酸受体调节蛋白和核酸分子及其用途
BE1014570A4 (fr) * 2002-01-11 2004-01-13 Sonaca Sa Procede de fabrication d'une structure cannelee et structure obtenue par ce procede.

Also Published As

Publication number Publication date
US6534289B1 (en) 2003-03-18
EP0783577B1 (de) 2008-07-09
WO1997005252A2 (en) 1997-02-13
US20030113873A1 (en) 2003-06-19
DE69637587D1 (de) 2008-08-21
JP2007006893A (ja) 2007-01-18
EP0783577A1 (de) 1997-07-16
ES2308779T3 (es) 2008-12-01
JPH10507934A (ja) 1998-08-04
US5981195A (en) 1999-11-09
AU710128B2 (en) 1999-09-16
IL120424A (en) 2008-12-29
IL120424A0 (en) 1997-07-13
AU6602296A (en) 1997-02-26
WO1997005252A3 (en) 1997-05-22
CA2200606A1 (en) 1997-02-13

Similar Documents

Publication Publication Date Title
DE69637587D1 (de) Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE69535498D1 (de) Verfahren zur behandlung vaskulärer kopfschmerzen
ATE58299T1 (de) Geraet zur behandlung neurovegetativer stoerungen.
DE69611251D1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69632743D1 (de) Verfahren zur regulierung des vagaltonus
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
ATE403437T1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis
DE69617235D1 (de) Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
ATE302194T1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
ATE315230T1 (de) Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE60023493D1 (de) Verwendung von synthetischen FXR Liganden zur Behandlung von Krankheiten die mit einem gestörten Gleichgewicht des Cholesterin-Spiegels verbunden sind und von Kolonkrebs
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE435026T1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE408840T1 (de) Verfahren zur identifizierung von agenzien zur behandlung von anfällen, neurologischen erkrankungen, endokrinopathien und hormonalen erkrankungen
ATE304855T1 (de) Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen
ATE368110T1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties